Anjana L.*1, Maharubasakthi B.1, Srimathi A.1, Dr. K. S. Swathi2, Amulthara L.3

PEMBROLIZUMAB AS AN IMMUNE CHECKPOINT INHIBITOR IN CANCER THERAPY

Cancer is characterized by uncontrolled proliferation of abnormal cells and the ability of malignant cells to evade immune surveillance. Immune checkpoint pathways, particularly the programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway, play an importan...